ZELTIQ® (pronounced Zel 'teek) was founded in 2005 with a clear, straightforward objective. Our mission is to create differentiated, clinically proven, safe, and beneficial solutions with one goal in mind: a cooler you.
Visionary Investors Meet Visionary Science
Companies are typically born from a single entrepreneur. The ZELTIQ story, however, is anything but typical.
Initial Cryolipolysis research was conducted by Drs. Dieter Manstein and R. Rox Anderson at the Wellman Center at Massachusetts General Hospital in Boston, a teaching affiliate for Harvard Medical School. This science and its potential served as the catalyst that attracted founding investors Advanced Technology Ventures (ATV) and Frazier Healthcare Ventures (FHV).
ATV is devoted to funding and helping manage the years of research and development needed to build the new ideas being created by innovators in health care and medical innovation. Since 1980, ATV has built a legacy of partnering with entrepreneurial teams at the forefront of the medical technology industry–developing ideas that lead markets and change the world.
FHV is passionate about supporting the growth of biopharma, medical device, and healthcare innovators. Since 1991, FHV has carefully built and developed a team of experts whose sole focus is on solving tomorrow's medical challenges. FHV has already invested in more than 100 successful companies, many of whom have teamed up with others in the FHV network.
The collaborative knowledge and insight of these three entities have played a significant role in ZELTIQ's efforts to develop this groundbreaking medical technology.
Founder of ZELTIQ
Investors at Frazier and ATV, led by Scott Wolf, negotiated the license and set up the Company and then recruited Mitch Levinson as founder to clinically prove efficacy whilst productizing the ideas of Drs. Manstein and Anderson. Mr. Levinson officially joined the company in September 2005 as President, and served on the board of directors, and as President and Chief Executive Officer from August 2006 to September 2009. He later held the position of Chief Scientific Officer from October 2009 to December 2010 before leaving the Company to pursue other opportunities.